MDx/CDx Focus: MolecularMD Grabs LKB1 Rights; Clarient Offering Qiagen KRAS Test; Inform's OnPART
January 30, 2013
MDx/CDx Focus: MolecularMD Grabs LKB1 Rights; Clarient Offering Qiagen KRAS Test; Inform's OnPART
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Dx Focus: Clarient to Offer Qiagen Therascreen KRAS Test as Erbitux CDx
January 31, 2013 / PCR Insider - GE's Clarient Purchase Heightens Company's Focus on Tests for Cancer Drug Personalization
October 27, 2010 / Pharmacogenomics Reporter - GE, Clarient Launching Biomarker Platform with 60-Plus Protein Multiplexing, Subcellular Resolution
February 15, 2013 / ProteoMonitor - Clarient to Offer Qiagen's Therascreen KRAS Assay as CDx for Erbitux
January 30, 2013 / GenomeWeb Daily News - Inform Genomics Developing SNP Test to Predict Side Effects, Help MDs Choose among Chemo Regimens
October 10, 2012 / Pharmacogenomics Reporter